FMA
ANIK icon

FNY Managed Accounts’s Anika Therapeutics ANIK Stock Holding History

FNY Managed Accounts’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-330
Closed -$14K – 188
2017
Q1 		$14K Buy
+330
New +$15.8K 0.04% 424

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

FNY Managed Accounts's ANIK Position: Q2 2017 in Review

FNY Managed Accounts sold out of Anika Therapeutics (ANIK) in Q2 2017, closing a stake of 330 shares — an estimated $14K sold.

FNY Managed Accounts first reported a position in ANIK in Q1 2017 and held it in 1 quarter. The position peaked at $14K in Q1 2017. 159 funds tracked by Wall St. Rank hold ANIK as of Q2 2017.

  • FNY Managed Accounts reported no remaining Anika Therapeutics position as of Q2 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 330 Anika Therapeutics shares in Q2 2017, an estimated $14K.
  • FNY Managed Accounts first reported a position in Anika Therapeutics in Q1 2017 and held it in 1 quarter.
  • FNY Managed Accounts's Anika Therapeutics position peaked at $14K in Q1 2017.
  • 159 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.